Grant: Alliance Grants
McMaster University
$30,000.00
Development of carrier-free terbium-161 for use in radiopharmaceuticals
EF 2023-24
Résumé
Targeted radiotherapy approach utilizes radiation to selectively target and destroy cancer cells. Terbium-161 is a promising radioisotope for targeted radiotherapy due to its nuclear properties, which provide high beta energy efficiency in combination with Auger emission. The radioisotope terbium-161 is currently in short supply due to its limited worldwide production capacity and growing demand for its use in targeted radiotherapy for cancer treatment. The preparation of terbium-161 involves the neutron activation of gadolinium-160. Traditional methods have used 160Ga(NO3)3 targets in a form of ampoules prepared from 160Gd2O3. A major limitation of the use of 160Ga(NO3)3 targets is the risk of production of water vapor during irradiation which leads to ampoule breakage and product loss. This limits the scale of production of terbium-161 to three times lower than the commercial no-carrier-added lutetium-177. Trace Science International has implemented novel irradiation conditions using 160Gd2O3 as a target and purification procedures to ensure higher capability of activity production of terbium-161 with high radionuclidic and radiochemical purity. Trace Sciences International aims to meet the growing demand for terbium-161 by providing an uninterrupted supply of terbium-161. McMaster's partnership with Trace Sciences International, provides a unique opportunity for Canada to become a leader in both production of terbium-161 and the development of novel 161Tb-labelled radiopharmaceuticals. Ensuring the domestic production of radioisotopes such as terbium-161 could help to mitigate the effects of future shortages and improve patient access to critical and emerging nuclear medicine radiopharmaceuticals.
Programme
Alliance Grants
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
586588-2023
Name nom
Sadeghi, Saman S
Department département
Chemistry & Chemical Biology
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2023
Competition year année de concours
2023
Award amount
30000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3501
Research subject group en
Analytical chemistry
Research subject group fr
Inorganic analytical chemistry
Research subject en
Chimie analytique
Research subject fr
Chimie analytique inorganique
Application title
Development of carrier-free terbium-161 for use in radiopharmaceuticals
Keyword
isotope separation; molecular imaging; purification; radiochemistry; terbium-161
Application summary
Targeted radiotherapy approach utilizes radiation to selectively target and destroy cancer cells. Terbium-161 is a promising radioisotope for targeted radiotherapy due to its nuclear properties, which provide high beta energy efficiency in combination with Auger emission. The radioisotope terbium-161 is currently in short supply due to its limited worldwide production capacity and growing demand for its use in targeted radiotherapy for cancer treatment. The preparation of terbium-161 involves the neutron activation of gadolinium-160. Traditional methods have used 160Ga(NO3)3 targets in a form of ampoules prepared from 160Gd2O3. A major limitation of the use of 160Ga(NO3)3 targets is the risk of production of water vapor during irradiation which leads to ampoule breakage and product loss. This limits the scale of production of terbium-161 to three times lower than the commercial no-carrier-added lutetium-177. Trace Science International has implemented novel irradiation conditions using 160Gd2O3 as a target and purification procedures to ensure higher capability of activity production of terbium-161 with high radionuclidic and radiochemical purity. Trace Sciences International aims to meet the growing demand for terbium-161 by providing an uninterrupted supply of terbium-161. McMaster's partnership with Trace Sciences International, provides a unique opportunity for Canada to become a leader in both production of terbium-161 and the development of novel 161Tb-labelled radiopharmaceuticals. Ensuring the domestic production of radioisotopes such as terbium-161 could help to mitigate the effects of future shortages and improve patient access to critical and emerging nuclear medicine radiopharmaceuticals.